• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

47.99 -0.45 (-0.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
36 37 Next >
News headline image
After Doubling in the Past 6 Months, Is This Stock a Buy? ↗
December 24, 2022
This company has had a solid year, but there is still plenty of work ahead. 
Via The Motley Fool
News headline image
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023? ↗
December 22, 2022
Crispr and Vertex are working toward the first submissions for a CRISPR-based product. 
Via Investor's Business Daily
News headline image
2 No-Brainer Biotech Stocks to Buy Right Now ↗
December 22, 2022
Vertex Therapeutics and Amgen have the building blocks for long-term success. 
Via The Motley Fool
News headline image
3 Cathie Wood Stocks That Could Make Big Comebacks in 2023 ↗
December 22, 2022
These businesses aren't in as much trouble as their stock returns suggest that they are. 
Via The Motley Fool
News headline image
3 Growth Stocks That Are Screaming Buys in December ↗
December 21, 2022
Don't let these companies pass you by the next time you go stock shopping. 
Via The Motley Fool
What 5 Analyst Ratings Have To Say About CRISPR Therapeutics ↗
November 23, 2022
 
Via Benzinga
News headline image
Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock ↗
December 18, 2022
Both stocks are heading for double-digit gains this year. 
Via The Motley Fool
News headline image
3 Beaten-Down Stocks That Could Explode Higher in 2023 ↗
December 17, 2022
These stocks could have significant upside opportunities ahead. 
Via The Motley Fool
News headline image
7 Stocks to Add to Your 10x Watchlist ↗
December 16, 2022
It’s always a good time to look for stocks with exceptional growth potential. Here are seven 10x stocks for your watchlist. 
Via InvestorPlace
News headline image
3 Growth Stocks With More Potential Than Any Cryptocurrency ↗
December 15, 2022
If the crypto meltdown has you discouraged, don't give up on stocks. 
Via The Motley Fool
News headline image
3 Red-Hot Stocks That Could Continue to Beat the Market ↗
December 11, 2022
The success these stocks achieved in 2022 could be just the beginning. 
Via The Motley Fool
News headline image
Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
December 10, 2022
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Want to Be Ready For a New Bull Market? Do These 3 Things Soon ↗
December 09, 2022
It's easier to make money in bull markets when you've done the prep work beforehand. 
Via The Motley Fool
News headline image
2 Growth Stocks That Could Help Set You Up for Life ↗
December 09, 2022
Many growth stocks are down, but they're not all out. 
Via The Motley Fool
News headline image
5 Best Bargain Stocks to Buy Before 2023 ↗
December 09, 2022
It's time to hit the best sale in town, and that involves many top stocks. 
Via The Motley Fool
News headline image
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation ↗
December 08, 2022
The three companies are changing the pharmaceutical industry. 
Via The Motley Fool
News headline image
Is CRISPR Therapeutics a Buy? ↗
December 08, 2022
A strong cash position could offset some of the near-term risks that come with owning the biotech. 
Via The Motley Fool
News headline image
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy ↗
December 08, 2022
-Clinical Data Due Next Week at ASH- 
Via Benzinga
News headline image
2 Unstoppable Growth Stocks to Buy in 2022 and Beyond ↗
December 08, 2022
These biotech players beat the bear market this year. 
Via The Motley Fool
News headline image
3 Fierce Stocks That Are Screaming Buys in December ↗
December 07, 2022
Here are three winners in the making. 
Via The Motley Fool
News headline image
Is It Too Late to Buy Vertex Pharmaceuticals Stock? ↗
December 06, 2022
The company has already made plenty of investors happy. 
Via The Motley Fool
News headline image
Bear Market Bargain Hunting: 3 Top Stocks to Buy Before 2023 ↗
December 06, 2022
These top players are ripe for recovery -- and long-term growth. 
Via The Motley Fool
News headline image
3 Growth Stocks That Are Too Cheap to Ignore ↗
December 01, 2022
Overlooking these stocks in the current market could be a mistake. 
Via The Motley Fool
News headline image
Cathie Wood Has Bet Big On These 10 Stocks; Here's How They're Performing ↗
November 28, 2022
Here's how Ark Invest's top holdings have performed in 2022. 
Via Investor's Business Daily
News headline image
2 Stocks Near 52-Week Highs That Could Climb Higher ↗
November 28, 2022
This pair of stocks are bucking the trend and they could climb even higher. 
Via The Motley Fool
News headline image
Cathie Wood Is Selling This High-Flying Stock. Here's Why You Should Buy It Instead ↗
November 25, 2022
The ARK Invest founder might regret trimming her position in this biotech stock. 
Via The Motley Fool
News headline image
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market ↗
November 23, 2022
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. 
Via Benzinga
News headline image
Where Will Editas Medicine Be in 1 Year? ↗
November 20, 2022
The company could continue lagging the market for a while. 
Via The Motley Fool
News headline image
2 Growth Stocks That Could Double in 2023 ↗
November 17, 2022
Both are lagging the market this year. 
Via The Motley Fool
News headline image
Crispr Therapeutics Stock: Bull vs. Bear ↗
November 15, 2022
Crispr shares have fallen about 20% so far this year. 
Via The Motley Fool
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap